Imatinib for patients with liver or kidney dysfunction: No need to modify the dose

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 521-522

  Judson, Ian R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; ANTICONVULSIVE AGENT; CARBOPLATIN; DOCETAXEL; DRUG METABOLITE; EPIRUBICIN; ETOPOSIDE; IMATINIB; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; WARFARIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANEMIA; AREA UNDER THE CURVE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL TUMOR; GRANULOCYTE; GRAPEFRUIT JUICE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; PRIORITY JOURNAL; SIDE EFFECT; DRUG MONITORING; KIDNEY DISEASE; LIVER DISEASE; NOTE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

ADMINISTRATION, ORAL; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG MONITORING; HUMANS; KIDNEY DISEASES; LIVER DISEASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 39149102893     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5110     Document Type: Editorial

References (22)

1. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
2. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
4. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
5. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
6. Peng B, Dutreix C, Mehring G, et al: Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158-162, 2004
7. Peng B, Hayes M, Resta D, et al: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935-942, 2004
8. Judson I, Ma P, Peng B, et al: Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time - EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379-386, 2005
9. Bolton AE, Peng B, Hubert M, et al: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106, 2004
10. Twelves CJ, Dobbs NA, Michael Y, et al: Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry tests. Br J Cancer 66:765-769, 1992
11. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
12. Joel SP, Shah R, Clark PI, et al: Predicting etoposide toxicity: Relationship to organ function and protein binding. J Clin Oncol 14:257-267, 1996
13. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
14. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
15. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005
16. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006
17. Gibbons J, Egorin ML, Ramanathan RK, et al: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:570-576, 2008
18. Ramanathan RK, Egorin MJ, Takimoto CHM, et al: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-569, 2008
19. Leblond F, Guevin C, Demers C, et al: Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326-332, 2001
20. Touchette MA, Slaughter RL: The effect of renal failure on hepatic drug clearance. Dicp 25:1214-1224, 1991
21. Dowling TC, Briglia AE, Fink JC, et al: Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427-434, 2003
22. Gambacorti-Passerini C, Zucchetti M, Russo D, et al: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625-632, 2003